IL-17F Protein, Human (Biotinylated, HEK293, His-Avi)
Based on 1 Customer Validation
IL-17F is an inflammatory homodimeric cytokine that induces many proinflammatory cytokines and chemokines. IL-17F also induces antimicrobial peptides. IL-17F plays a protective role in colon cancer development and can be used for the research of autoimmune diseases, infection and cancer. IL-17F Protein, Human (Biotinylated, HEK293, His-Avi) is a biotinylated recombinant human IL-17F protein with His and Avi tags at the C-terminus and is expressed in HEK293 cells. It consists of 133 amino acids (R31-Q163).
- Species: Human
- Source: HEK293
-
Storage:Stored at -20°C for 2 years from date of receipt. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.
Biological Activity
Description
IL-17F is an inflammatory homodimeric cytokine that induces many proinflammatory cytokines and chemokines. IL-17F also induces antimicrobial peptides. IL-17F plays a protective role in colon cancer development and can be used for the research of autoimmune diseases, infection and cancer[1][2]. IL-17F Protein, Human (Biotinylated, HEK293, His-Avi) is a biotinylated recombinant human IL-17F protein with His and Avi tags at the C-terminus and is expressed in HEK293 cells. It consists of 133 amino acids (R31-Q163).
Background
Interleukin-17F (IL-17F) belongs to the IL-17 cytokine family. IL-17F is expressed in activated CD4 T cells, activated monocytes, basophils and mast cells. IL-17F can be produced by differentiated TH17 cells, lamina propria T cells, memory CD4+ T cells, γδ T cells and NKT cells[1].
The human IL-17F shares 55.90% amino acid sequence identity with mouse and 57.14% identity with rat.
IL-17F is an inflammatory cytokine that induces many proinflammatory cytokines and chemokines, including TGF-β, IL-2, ICAM1, GM-CSF, CCL2, CCL7, TSLP, MMP13, IL-6 and CXCL1. IL-17F also induces antimicrobial peptides including hBD-2, S100A7, S100A8 and S100A9 with IL-22 and can synergize with IL-23 in human eosinophils to promote the production of IL-1β and IL-6. IL-17F is a homodimeric cytokine. IL-17F shares the most similarities with IL-17A (50% homology) and can be produced as an IL-17AF heterodimer. IL-17A, IL-17F and IL-17A/F use the same receptor complex: IL-17RA and IL-17RC heterodimer. They trigger qualitatively similar signaling pathways, and IL-17F exhibits the lowest biological activity. IL-17F shows about 100–1000 times lower affinity to the IL-17RA subunit than IL-17A, and does not compete with IL-17A binding to IL-17RA[1][2].
IL-17F plays a protective role in colon cancer development and can be used for the research of autoimmune diseases, infection and cancer[1][3][4].
In Vivo
IL-17F (5 ng/mL; 16-24 h) induces GRO-α, IL-6, and IL-8 secretion in human primary foreskin fibroblast (BJ) cells[5].
IL-17F binds weakly to IL-17RA.Fc with an EC5 > 2 ng/mL, whereas IL-17A binds IL-17RA.Fc with a value of 19 ng/mL, the IL-17F/IL-17A heterodimer has an EC5 of 329 ng/mL[5].
IL-17F (-15 ng/mL; -72 h) increases the cell viability of PC-3 and DU145[6].
IL-17F (1 ng/mL; 24 h) stimulates the malignant phenotypes of PCa cells and activates PI3K/AKT signalling pathway in PCa cells[6].
Verified Bioactivity
1. Immobilized Human IL-17 R alpha, hFc Tag at 2μg/ml (100μl/well) on the plate. Dose response curve for Biotinylated Human IL-17F, His Tag with the EC50 of 1.16 μg/ml determined by ELISA.
2. Immobilized Biotinylated Human IL-17F , His Avi Tag at 2μg/ml (100μl/well) on the streptavidin precoated plate (5μg/ml). Dose response curve for Human IL-17 R alpha, hFc Tag with the EC50 of 0.31μg/ml determined by ELISA.
Technical Parameters
-
Species Human
-
Source HEK293
-
Tag C-Avi;C-6*His
-
Accession
Q96PD4 (R31-Q163)
-
Molecular Construction
-
N-term
-
IL-17F (R31-Q163)
Accession # Q96PD4 -
6*His-Avi
-
C-term
-
-
Protein Length
Full Length of Mature Protein
-
Conjugation
Biotin
-
Synonyms
IL17F; ML1; Interleukin 17F; Interleukin-17F; IL-17F; Cytokine ML-1; ML-1; CANDF6
-
AA Sequence
RKIPKVGHTFFQKPESCPPVPGGSMKLDIGIINENQRVSMSRNIESRSTSPWNYTVTWDPNRYPSEVVQAQCRNLGCINAQGKEDISMNSVPIQQETLVVRRKHQGCSVSFQLEKVLVTVGCTCVTPVIHHVQ
-
Predicted Molecular Mass
17.5 kDa & 14.9 kDa
-
Molecular Weight
Approximately 23-28 kDa, based on SDS-PAGE under reducing conditions, due to the glycosylation.
-
Glycosylation
Yes
-
Purity
≥ 95%, as determined by Bis-Tris PAGE.
Product Properties
Lyophilized powder.
Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.4, 8% trehalose.
<1 EU/μg, determined by LAL method.
It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH2O.
Stored at -20°C for 2 years from date of receipt. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.
Room temperature in continental US; may vary elsewhere.
Documentation
-
Data Sheet (264 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Chang SH, et al. IL-17F: regulation, signaling and function in inflammation. Cytokine. 2009 Apr;46(1):7-11. [Content Brief]
[2]. McGeachy MJ, et al. The IL-17 Family of Cytokines in Health and Disease. Immunity. 2019 Apr 16;50(4):892-906. [Content Brief]
[3]. Ferreira N, et al. IL-17A and IL-17F orchestrate macrophages to promote lung cancer. Cell Oncol (Dordr). 2020 Aug;43(4):643-654. [Content Brief]
[4]. Tong Z, et al. A protective role by interleukin-17F in colon tumorigenesis. PLoS One. 2012;7(4):e34959. [Content Brief]
[5]. Wright JF, et al. The human IL-17F/IL-17A heterodimeric cytokine signals through the IL-17RA/IL-17RC receptor complex. J Immunol. 2008 Aug 15;181(4):2799-805. [Content Brief]
[6]. Zhu X, et al. IL-17F facilitates prostate cancer cell malignant phenotypes via activation of the PI3K/AKT signalling pathway. Andrologia. 2020 Nov;52(10):e13750. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)